March 23 (Reuters) - Gilead Sciences ( GILD ) is nearing an acquisition of Ouro Medicines, a biotech focused on immune disorder treatments, for up to $2 billion, the Financial Times reported on Monday.

Under the terms of the deal, Gilead will pay privately held Ouro's investors roughly $1.5 billion upfront in cash and at least an additional $500 million if certain clinical trial milestones are hit, the report said, ​citing people familiar with ​the matter.

The deal could be announced in the coming days, the report said, adding that the timing and terms could change.

Gilead and California-based Ouro Medicines did not immediately respond to Reuters' requests for comment.